Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tempest Therapeutics, Inc. (TPST : NSDQ)

• Company Description    Tempest Therapeutics Inc. is a clinical-stage oncology company developing potentially first-in-class therapeutics which combines both targeted and immune-mediated mechanisms. Tempest Therapeutics Inc., formerly known as Millendo Therapeutics Inc., is based in Calif. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $7.36 Daily Weekly Monthly 20 Day Moving Average: 81,015 shares Shares Outstanding: 3.68 (millions) Market Capitalization: $27.10 (millions) Beta: -1.95 52 Week High: $30.03 52 Week Low: $5.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.52% -0.36% 12 Week 1.10% -14.96% Year To Date -32.18% -36.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2000 SIERRA POINT PARKWAY SUITE 400 - BRISBANE,CA 94005 USA ph: 415-798-8589 fax: - swheeler@wheelhouselsa.com http://www.tempesttx.com

• General Corporate Information    Officers Stephen Brady - Chief Executive Officer; President and Director Michael Raab - Chairman of the Board of Directors Nicholas Maestas - Chief Financial Officer & Head of Corporate Strate Justin Trojanowski - Corporate Controller; Treasurer Geoff Nichol - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 87978U207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 3.68 Most Recent Split Date: 4.00 (0.08:1) Beta: -1.95 Market Capitalization: $27.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-11.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.42 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 32.50% vs. Previous Quarter: 21.61% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -305.51 12/31/24 - -245.58 ROA 06/30/25 - - 03/31/25 - -119.74 12/31/24 - -103.40 Current Ratio 06/30/25 - - 03/31/25 - 1.70 12/31/24 - 2.21 Quick Ratio 06/30/25 - - 03/31/25 - 1.70 12/31/24 - 2.21 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 3.05 12/31/24 - 5.66 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©